Effect of PD-L1 expression on the efficacy of pemetrexed-based chemotherapy in patients with advanced lung adenocarcinoma and its mechanism
Background and purpose: The expression of programmed death ligand-1 (PD-L1) in lung cancer not only is the most important biomarker for predicting the efficacy of programmed death-1 (PD-1)/PD-L1 inhibitors, but also may affect the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) targeted therapy. However, there are currently few reports in the relevant literature on whether the expression of PD-L1 in lung cancer can affect the efficacy of chemotherapy in patients with lung adenocarcinoma. This study mainly explored the effect of PD-L1 expression in lung adenocarcinoma on the efficacy of pemetrexed-based chemotherapy and its underlying mechanism. Methods: From Oct. 2015 to Dec. 2018, 185 eligible lung adenocarcinoma patients treated in Department of Pathology, The General Hospital of Western Theater Command PLA were enrolled. The expressions of PD-L1 and thymidylate synthase (TS), a molecule predicting the efficacy of pemetrexed-based chemotherapy, were detected by immunohistochemistry. The survival curve of patients was drawn by Kaplan-Meier method. The log-rank test and COX regression model were used to analyze the clinicopathological factors affecting the patients’ progression-free survival (PFS) and overall survival (OS). The log-rank test was used to analyze the effects of PD-L1 and TS expressions on the patients’ PFS and OS. Spearman rank correlation test was used to analyze the correlation between PD-L1 expression and TS expression in lung cancer tissues. Western blot and real-time fluorescent quantitative polymerase chain reaction (RTFQ-PCR) were used to detect the protein and mRNA expressions of PD-L1 and TS in 6 types of lung adenocarcinoma cell lines. The Pearson correlation test was used to analyze the correlation between PD-L1 and TS at protein expression level and mRNA expression level. Results: Among 51 patients with advanced lung adenocarcinoma who received pemetrexed-based chemotherapy as first-line treatment, the objective response rate (ORR) of the PD-L1 positive group was 20.0%, and the disease control rate (DCR) was 60.0%. There was no significant difference compared with the PD-L1 negative group (ORR: 20.0% vs 35.5%, χ 2 =1.404, P=0.236; DCR: 60.0% vs 80.6%, χ 2 =2.602, P=0.107). The median PFS (mPFS) of patients with negative expression of PD-L1 was significantly better than that of patients with positive expression of PD-L1 (mPFS: 5.6 months vs 4.1 months, log-rank=5.406, P=0.020), and there was no significant difference in median OS (mOS) between them (mOS: 15.9 months vs 12.7 months, log-rank=0.525, P=0.469). Univariate analysis found that the positive expressions of PD-L1 and TS were risk factors for PFS [PD-L1 negative vs positive: HR=2.002 (1.100-3.645), P=0.023; TS negative vs positive: HR=2.205 (1.367-4.587), P=0.003]. Multivariate analysis found that TS positive expression was an independent risk factor for PFS [TS negative vs positive: HR=3.245 (1.091-9.652), P=0.034]. Among the 51 patients with advanced lung adenocarcinoma who received pemetrexed-based chemotherapy as the first-line treatment, the expression of PD-L1 in cancer tissues was significantly positively correlated with the expression of TS (r s =0.691, P<0.001). We further compared the subjects after expanding to 185 patients of lung adenocarcinoma with different tumor stages and first-line treatments, and the expressions of PD-L1 and TS in cancer tissues still showed a significant positive correlation (r s =0.588, P<0.001). In 6 types of lung cancer cell lines including A549 and H1437, the expressions of PD-L1 and TS at the protein level and mRNA level were significantly positively correlated (protein expression level: r s =0.899, P<0.05; mRNA expression level: r s =0.861, P<0.05). Conclusion: In patients with advanced lung adenocarcinoma who received pemetrexed as the first-line chemotherapy, the PFS of patients with positive PD-L1 expression was significantly shorter than that of patients with negative PD-L1 expression, suggesting that PD-L1 expression may be used as a potential biomarker for predicting the efficacy of pemetrexed-based chemotherapy. There is a significant correlation between the expressions of PD-L1 and TS in both lung adenocarcinoma tissues and lung cancer cell lines, which may be one of the potential reasons why the expression of PD-L1 affects the efficacy of pemetrexed-based chemotherapy..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
---|---|
Enthalten in: |
Zhongguo aizheng zazhi - 31(2021), 4, Seite 308-316 |
Sprache: |
Englisch ; Chinesisch |
---|
Beteiligte Personen: |
SHI Maolin , BAI Yudi , WANG Chao , LI Siqi , ZHOU Daijun , PENG Jingjing , SUN Feifan , LI Dong , ZHANG Tao [VerfasserIn] |
---|
Links: |
doi.org [kostenfrei] |
---|
Themen: |
Lung adenocarcinoma| pd-l1|thymidylate synthase| pemetrexed |
---|
doi: |
10.19401/j.cnki.1007-3639.2021.04.010 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
DOAJ029091349 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ029091349 | ||
003 | DE-627 | ||
005 | 20230502130450.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230226s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.19401/j.cnki.1007-3639.2021.04.010 |2 doi | |
035 | |a (DE-627)DOAJ029091349 | ||
035 | |a (DE-599)DOAJfb0329738aef4f5c9959a5947e74a34d | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng |a chi | ||
050 | 0 | |a RC254-282 | |
100 | 0 | |a SHI Maolin , BAI Yudi , WANG Chao , LI Siqi , ZHOU Daijun , PENG Jingjing , SUN Feifan , LI Dong , ZHANG Tao |e verfasserin |4 aut | |
245 | 1 | 0 | |a Effect of PD-L1 expression on the efficacy of pemetrexed-based chemotherapy in patients with advanced lung adenocarcinoma and its mechanism |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Background and purpose: The expression of programmed death ligand-1 (PD-L1) in lung cancer not only is the most important biomarker for predicting the efficacy of programmed death-1 (PD-1)/PD-L1 inhibitors, but also may affect the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) targeted therapy. However, there are currently few reports in the relevant literature on whether the expression of PD-L1 in lung cancer can affect the efficacy of chemotherapy in patients with lung adenocarcinoma. This study mainly explored the effect of PD-L1 expression in lung adenocarcinoma on the efficacy of pemetrexed-based chemotherapy and its underlying mechanism. Methods: From Oct. 2015 to Dec. 2018, 185 eligible lung adenocarcinoma patients treated in Department of Pathology, The General Hospital of Western Theater Command PLA were enrolled. The expressions of PD-L1 and thymidylate synthase (TS), a molecule predicting the efficacy of pemetrexed-based chemotherapy, were detected by immunohistochemistry. The survival curve of patients was drawn by Kaplan-Meier method. The log-rank test and COX regression model were used to analyze the clinicopathological factors affecting the patients’ progression-free survival (PFS) and overall survival (OS). The log-rank test was used to analyze the effects of PD-L1 and TS expressions on the patients’ PFS and OS. Spearman rank correlation test was used to analyze the correlation between PD-L1 expression and TS expression in lung cancer tissues. Western blot and real-time fluorescent quantitative polymerase chain reaction (RTFQ-PCR) were used to detect the protein and mRNA expressions of PD-L1 and TS in 6 types of lung adenocarcinoma cell lines. The Pearson correlation test was used to analyze the correlation between PD-L1 and TS at protein expression level and mRNA expression level. Results: Among 51 patients with advanced lung adenocarcinoma who received pemetrexed-based chemotherapy as first-line treatment, the objective response rate (ORR) of the PD-L1 positive group was 20.0%, and the disease control rate (DCR) was 60.0%. There was no significant difference compared with the PD-L1 negative group (ORR: 20.0% vs 35.5%, χ 2 =1.404, P=0.236; DCR: 60.0% vs 80.6%, χ 2 =2.602, P=0.107). The median PFS (mPFS) of patients with negative expression of PD-L1 was significantly better than that of patients with positive expression of PD-L1 (mPFS: 5.6 months vs 4.1 months, log-rank=5.406, P=0.020), and there was no significant difference in median OS (mOS) between them (mOS: 15.9 months vs 12.7 months, log-rank=0.525, P=0.469). Univariate analysis found that the positive expressions of PD-L1 and TS were risk factors for PFS [PD-L1 negative vs positive: HR=2.002 (1.100-3.645), P=0.023; TS negative vs positive: HR=2.205 (1.367-4.587), P=0.003]. Multivariate analysis found that TS positive expression was an independent risk factor for PFS [TS negative vs positive: HR=3.245 (1.091-9.652), P=0.034]. Among the 51 patients with advanced lung adenocarcinoma who received pemetrexed-based chemotherapy as the first-line treatment, the expression of PD-L1 in cancer tissues was significantly positively correlated with the expression of TS (r s =0.691, P<0.001). We further compared the subjects after expanding to 185 patients of lung adenocarcinoma with different tumor stages and first-line treatments, and the expressions of PD-L1 and TS in cancer tissues still showed a significant positive correlation (r s =0.588, P<0.001). In 6 types of lung cancer cell lines including A549 and H1437, the expressions of PD-L1 and TS at the protein level and mRNA level were significantly positively correlated (protein expression level: r s =0.899, P<0.05; mRNA expression level: r s =0.861, P<0.05). Conclusion: In patients with advanced lung adenocarcinoma who received pemetrexed as the first-line chemotherapy, the PFS of patients with positive PD-L1 expression was significantly shorter than that of patients with negative PD-L1 expression, suggesting that PD-L1 expression may be used as a potential biomarker for predicting the efficacy of pemetrexed-based chemotherapy. There is a significant correlation between the expressions of PD-L1 and TS in both lung adenocarcinoma tissues and lung cancer cell lines, which may be one of the potential reasons why the expression of PD-L1 affects the efficacy of pemetrexed-based chemotherapy. | ||
650 | 4 | |a lung adenocarcinoma| pd-l1|thymidylate synthase| pemetrexed | |
653 | 0 | |a Neoplasms. Tumors. Oncology. Including cancer and carcinogens | |
773 | 0 | 8 | |i In |t Zhongguo aizheng zazhi |d Editorial Office of China Oncology, 2022 |g 31(2021), 4, Seite 308-316 |w (DE-627)DOAJ078621666 |x 10073639 |7 nnns |
773 | 1 | 8 | |g volume:31 |g year:2021 |g number:4 |g pages:308-316 |
856 | 4 | 0 | |u https://doi.org/10.19401/j.cnki.1007-3639.2021.04.010 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/fb0329738aef4f5c9959a5947e74a34d |z kostenfrei |
856 | 4 | 0 | |u http://www.china-oncology.com/fileup/1007-3639/PDF/20210410.pdf |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1007-3639 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |d 31 |j 2021 |e 4 |h 308-316 |